RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.44
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$28.34

16 Jul
2026

0.600

OPEN

$28.18

2.16%

HIGH

$28.34

802,369

LOW

$28.18

TARGET
$39.543 39.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) 163.2 xxx
DPS (cps) 35.9 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 17.7 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 22.0% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.93%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.05

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 13/05 - (franking ex-div 5.90c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx147.4
DPS All xxxxxxxxxxxxxxx32.5
Sales/Revenue xxxxxxxxxxxxxxx7,946.4 M
Book Value Per Share xxxxxxxxxxxxxxx622.1
Net Operating Cash Flow xxxxxxxxxxxxxxx2,704.6 M
Net Profit Margin xxxxxxxxxxxxxxx27.22 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx26.39 %
Return on Invested Capital xxxxxxxxxxxxxxx22.91 %
Return on Assets xxxxxxxxxxxxxxx19.00 %
Return on Equity xxxxxxxxxxxxxxx26.39 %
Return on Total Capital xxxxxxxxxxxxxxx27.43 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx2,085.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx62 M
Long Term Debt xxxxxxxxxxxxxxx1,238 M
Total Debt xxxxxxxxxxxxxxx1,300 M
Goodwill - Gross xxxxxxxxxxxxxxx4,649 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx1,865 M
Price To Book Value xxxxxxxxxxxxxxx6.33

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx155.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.96 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,299 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2,042 M
Research & Development xxxxxxxxxxxxxxx512 M
Investments - Total xxxxxxxxxxxxxxx108 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

09/07/2026

1

Outperform

$46.60

64.43%

ResMed has sold its MatrixCare business for US$490m in an all-cash deal with Frazier Healthcare Partners. Macquarie considers this divestment strategically sound, allowing the company to focus on faster-growing core areas.

The MatrixCare care end markets have structural headwinds amid lower patient volumes post Covid. Net proceeds from the transaction will be returned to shareholders and for general corporate purposes.

The company also provided an update on the Noctrix acquisition, with US$30m in revenue expected in FY27 albeit dilutive to EPS by -US$0.20. The broker maintains an Outperform rating and the target edges up to $46.60 from $46.50.

FORECAST
Macquarie forecasts a full year FY26 dividend of 35.25 cents and EPS of 163.04 cents.
Macquarie forecasts a full year FY27 dividend of 37.02 cents and EPS of 181.26 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

05/05/2026

1

Buy

$44.50

57.02%

Canaccord Genuity maintains a Buy rating for ResMed, lowering the target price to $44.50 from $46.50 following the release of what is assessed as a robust third-quarter result.

Gross margins expanded 290 basis points to 62.2%, benefiting from efficiency programs, improved supply contracts, and favourable freight mixes.

The broker notes broader healthcare sector de-rating and noise surrounding GLP-1 weight loss drugs continue weighing on market sentiment, though these present intrinsically remediable challenges.

The recent US$340m acquisition of Noctrix Health creates a near-term -US2.0c earnings headwind per share, prompting minor downward revisions to near-term forecasts.

Unfavourable currency translation movements primarily drove the reduction in the final valuation.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 35.99 cents and EPS of 162.46 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 38.48 cents and EPS of 179.79 cents.
Access Extra Coverage Research History >

RMD STOCK CHART

FNArena News on RMD

1
ESG Focus: War Accelerates Energy Transition

Jul 15 2026 - ESG Focus
2
Rudi’s View: Telstra’s Premium Under Scrutiny

Jul 15 2026 - Rudi's View
3
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
4
Australian Broker Call *Extra* Edition – Jul 13, 2026

Jul 13 2026 - Daily Market Reports
5
Next Week At A Glance – 13-17 Jul 2026

Jul 10 2026 - Weekly Reports

Latest Medical Equipment & Devices News

1
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
2
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
3
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
4
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
5
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
6
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
7
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
8
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
9
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
10
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest